A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs SHR 1316 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 30 May 2019 to 30 Sep 2019.
- 26 Feb 2019 Planned End Date changed from 30 Mar 2019 to 30 May 2019.